Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Ten years of hormone therapy reduces breast cancer recurrence without compromising quality of life

2016 ASCO Annual Meeting

Published: 5 Jun 2016

Views: 1911

Rating:

Save

Dr Julie Lemieux - Hôpital du Saint-Sacrement, Québec, Canada

Dr Lemieux presents at ASCO 2016, a randomised phase III clinical trial, MA.17R found that postmenopausal women with early breast cancer benefit from extending aromatase inhibitor (AI) therapy with letrozole from 5 to 10 years.

Read the news story or watch the video interview for more.

Related Videos

Post-diagnosis diet, nutrition and cancer prognosis

Dr Doris Chan - Imperial College London, London, UK

Post-diagnosis diet, nutrition and cancer prognosis ( Dr Doris Chan - Imperial College London, London, UK )

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2...

Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies ( Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA )

Trastuzumab deruxtecan effective against brain metastases in HER2-positive...

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )

Patient reported outcomes for telisotuzumab vedotin in c-Met protein...

Prof Nicolas Girard - Institut Curie, Paris, France

Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Breastfeeding after breast cancer is safe

Dr Eva Blondeaux - Ospedale San Martino, Genova, Italy

Breastfeeding after breast cancer is safe ( Dr Eva Blondeaux - Ospedale San Martino, Genova, Italy )

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival...

Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach...

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC ( Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany )

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Genomic testing: Awareness and effective communication between healthcare...

Prof Richard Simcock and Antonella Cardone

Genomic testing: Awareness and effective communication between healthcare professionals and patients ( Prof Richard Simcock and Antonella Cardone )

Advancing breast cancer treatment in Uganda by improving molecular testing

Dr Jackson Orem - Uganda Cancer Institute, Kampala, Uganda

Advancing breast cancer treatment in Uganda by improving molecular testing ( Dr Jackson Orem - Uganda Cancer Institute, Kampala, Uganda )

More from ecancer